<DOC>
	<DOCNO>NCT02617784</DOCNO>
	<brief_summary>This study design assess pharmacokinetics ( PK ) safety oseltamivir metabolite oseltamivir carboxylate participant undergo routine HD CAPD end-stage renal disease ( ESRD ) . Participants receive 6.5 6 week market oral oseltamivir suspension dose accord HD CAPD schedule , respectively .</brief_summary>
	<brief_title>A Multiple-Dose Study Oral Oseltamivir Participants Hemodialysis ( HD ) Continuous Ambulatory Peritoneal Dialysis ( CAPD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Adults great equal ( &gt; /= ) 18 year age ESRD define residual renal function creatinine clearance ( CrCl ) less ( &lt; ) 10 milliliter per minute ( mL/min ) Well establish HD CAPD therapy period 3 month stable CrCl &lt; 10 mL/min Body mass index ( BMI ) 18 34 kilogram per metersquared ( kg/m^2 ) Use contraception among woman childbearing potential Clinical significant comorbid disease terminal illness Known human immunodeficiency virus ( HIV ) hepatitis B C History drug alcohol abuse within prior year Donation loss &gt; /= 400 milliliter ( mL ) blood 3 month prior Screening Participation clinical study investigational drug 3 month prior study drug Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>